We are developing an innovative and proprietary method of allogeneic hematopoietic stem cell transplantation with the potential to transform the standard of care across numerous therapeutic areas.
With Facilitated Allo-HSCT Therapy, we aim to remove solid organ transplantation recipients’ need for chronic immunosuppression and treat patients who suffer from severe autoimmune diseases and certain severe non-malignant blood, immune and metabolic disorders.
Talaris has launched a multi-center, Phase 3 clinical trial of FCR001 in living donor kidney transplant patients, to assess the efficacy and safety of FCR001 in weaning patients off all chronic immunosuppression by twelve months post-transplant.
BOSTON and LOUISVILLE, Ky., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and... READ MORE
On track to provide FREEDOM-1 initial clinical update, initiate FREEDOM-2 and FREEDOM-3 trials, and to disclose additional indication for FCR001 before year-end BOSTON and LOUISVILLE, Ky., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell... READ MORE